Article
Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen Radioligand Therapy.
JCO precision oncology - 1 Dec 2024
Wenzel Mike, Koll Florestan, Hoeh Benedikt, Humke Clara, Reis Henning, Wild Peter, Steuber Thomas, Graefen Markus, Tilki Derya, Sabet Amir, Gröner Daniel, Chun Felix K H, Mandel Philipp
Abstract excerpt
PURPOSE: Several tumor gene mutations are known for metastatic castration-resistant prostate cancer (mCRPC). The individual response to 177-lutetium prostate specific membrane antigen radioligand therapy (Lu-PSMA) is under current investigation regarding the genomic profile of patients with mCRPC. MATERIALS AND METHODS: We relied on the FRAMCAP database and compared progression-free survival (PFS) and overall...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.